8-benzyl-1,4-dioxaspiro[4.5]decan-8-ol | 607744-45-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 8-benzyl-1,4-dioxaspiro[4.5]decan-8-ol
• CAS: 607744-45-6
• 化学式: C₁₅H₂₀O₃
• 分子量: 248.322
• InChiKey: WMIIZRITOLQVDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-benzyl-1,4-dioxaspiro[4.5]decan-8-ol 在 三氟乙酸 、 2% active carbon-supported palladium 、 氢气 作用下， 生成 4-苯基甲基环己酮
  参考文献：
  名称：

  噻唑啉基亚氨基喹啉钴催化烯烃去对称异构化

  摘要：

  我们报道了一种钴催化的外环烯烃去对称异构化，以产生具有良好收率和对映选择性的手性 1-甲基环己烯衍生物。设计并合成了一种新型手性噻唑啉基亚氨基喹啉配体及其钴配合物，以控制在偏远位置建立叔或季碳中心。该协议操作简单，并提出了立体化学结果的模型。

  DOI：

  10.1021/acs.orglett.1c04237
• 作为产物：
  描述：

  1,4-环己二酮单乙二醇缩酮 、 苄基氯化镁 在 氯化铵 、 乙酸乙酯 、 水 、 Brine 、 Sodium sulfate-III 、 silica gel 、 hexanes ethyl acetate 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以to provide the desired product (8.08 g, 81%)的产率得到8-benzyl-1,4-dioxaspiro[4.5]decan-8-ol
  参考文献：
  名称：

  N-sulfonylurea apoptosis promoters

  摘要：

  化合物的化学式为，具有促进细胞凋亡的作用。本文还公开了制备这些化合物的方法，含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。

  公开号：

  US20060074085A1

文献信息

• Application of Transaminases in a Disperse System for the Bioamination of Hydrophobic Substrates
  作者：Andrea Fiorati、Per Berglund、Maria S. Humble、Davide Tessaro

  DOI：10.1002/adsc.201901434

  日期：2020.3.4

  The challenging bioamination of hydrophobic substrates has been attained through the employment of a disperse system consisting of a combination of a low polarity solvent (e. g. isooctane or methyl‐tert‐butylether), a non‐ionic surfactant and a minimal amount of water. In these conditions, amine transaminases (ATA) were shown to efficiently carry out the reductive amination of variously substituted

  通过使用由低极性溶剂（例如异辛烷或甲基叔丁基醚），非离子表面活性剂和少量水组成的分散体系，可以实现疏水性底物具有挑战性的生物胺化作用。在这些条件下，胺转氨酶（ATA）被证明可以有效地进行各种取代的环己酮的还原胺化，与相应的化学还原胺化反应相比，可以提供良好的转化率，同时还具有出色的立体选择性。因此，通过生物催化合成，合成和表征了一系列有用的4-取代的氨基环己烷。
• CYCLOHEXYL(ALKYL)PROPANOLAMINES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
  申请人：Bovy Philippe R.

  公开号：US20080261949A1

  公开（公告）日：2008-10-23

  The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an —S(O) z (C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —SO 2 NH(C 1 -C 4 )alkyl group, an —NHSO 2 phenyl-(C 1 -C 4 )alkyl group or an —NHSO 2 phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C 1 -C 4 )alkyl group or with a (C 1 -C 4 )alkoxy group; R 1 represents a hydrogen atom or a (C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, a phenyl-(C 1 -C 4 )alkyl group or a —COphenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C 1 -C 4 )alkoxy group; R 2 is a hydrogen atom or an —SO 2 (C 1 -C 4 )alkyl group, an —SO 2 phenyl-(C 1 -C 4 )alkyl group or an —SO 2 phenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C 1 -C 4 )alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; R 3 represents a hydrogen or halogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 4 )alkoxy group, a —COO(C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —NHSO 2 phenyl-(C 1 -C 4 )alkyl groups, —NO 2 , —CN, —CONR 4 R 5 , —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; R 4 and R 5 represent, independently, a hydrogen atom, a phenyl, a (C 1 -C 4 )alkyl group or a phenyl-(C 1 -C 4 )alkyl group or R 4 and R 5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.

  本发明涉及公式（I）的化合物： 其中A是公式（a）或（b）的基团： 其中R表示氢或卤素原子，-S（O）z（C1-C4）烷基，-NHSO2（C1-C4）烷基，-SO2NH（C1-C4）烷基，-NHSO2苯基-（C1-C4）烷基或-NHSO2苯基，所述苯基可能被卤素原子，（C1-C4）烷基或（C1-C4）氧烷基取代； R1表示氢原子或（C1-C4）烷基，-CO（C1-C4）烷基，苯基-（C1-C4）烷基或-CO苯基，所述苯基也可能被卤素原子或（C1-C4）氧烷基取代； R2是氢原子或-SO2（C1-C4）烷基，-SO2苯基-（C1-C4）烷基或-SO2苯基； X完成由5到8个原子组成的环，该环饱和或不饱和，可能被一个或两个（C1-C4）烷基取代，并带有一个或两个羰基基团； n，m和z独立地为0、1或2； R3表示氢或卤素原子，（C1-C6）烷基，（C1-C4）氧烷基，-COO（C1-C4）烷基，-CO（C1-C4）烷基，-NHSO2（C1-C4）烷基，-NHSO2苯基-（C1-C4）烷基，-NO2，-CN，-CONR4R5，-COOH或4,5-二氢-1,3-噁唑-2-基或4,4-二甲基-4,5-二氢-1,3-噁唑-2-基； R4和R5独立地表示氢原子，苯基，（C1-C4）烷基或苯基-（C1-C4）烷基，或R4和R5与它们附着的氮原子一起可以形成总共5到7个原子的环；以及其盐或溶剂，含有它们的制药组合物，制备过程和其中间体的本发明。
• Cyclohexyl(alkyl)propanolamines, Preparation Method and Pharmaceutical Compositions Containing Same
  申请人：BOVY R. Philippe

  公开号：US20070015745A1

  公开（公告）日：2007-01-18

  The present invention relates to the compounds of formula (I): in which A is a group of formula (a) or (b) in which R represents a hydrogen or halogen atom, an —S(O) z (C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —SO 2 NH(C 1 -C 4 )alkyl group, an —NHSO 2 phenyl-(C 1 -C 4 )alkyl group or an —NHSO 2 phenyl group, said phenyl possibly being substituted with a halogen atom, with a (C 1 -C 4 )alkyl group or with a (C 1 -C 4 )alkoxy group; R 1 represents a hydrogen atom or a (C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, a phenyl-(C 1 -C 4 )alkyl group or a —CO—phenyl group, said phenyl also possibly being substituted with a halogen atom or with a (C 1 -C 4 )alkoxy group; R 2 is a hydrogen atom or an —SO 2 (C 1 -C 4 )alkyl group, an —SO 2 phenyl-(C 1 -C 4 )alkyl group or an —SO 2 phenyl group; X completes a ring of 5 to 8 atoms, said ring being saturated or unsaturated, possibly being substituted with one or two (C 1 -C 4 )alkyl groups and bearing one or two carbonyl groups; n, m and z are, independently, 0, 1 or 2; R 3 represents a hydrogen or halogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 4 )alkoxy group, a —COO(C 1 -C 4 )alkyl group, a —CO(C 1 -C 4 )alkyl group, an —NHSO 2 (C 1 -C 4 )alkyl group, an —NHSO 2 phenyl-(C 1 -C 4 )alkyl groups, —NO 2 , —CN, —CONR 4 R 5 , —COOH, or a 4,5-dihydro-1,3-oxazol-2-yl or 4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl group; R4 and R 5 represent, independently, a hydrogen atom, a phenyl, a (C 1 -C 4 )alkyl group or a phenyl-(C 1 -C 4 )alkyl group or R 4 and R 5 with the nitrogen atom to which they are attached, may form a ring of 5 to 7 atoms in total; and to the salts or solvates thereof, to the pharmaceutical compositions containing them, to a process for the preparation thereof and to intermediates in this process.

  本发明涉及式(I)的化合物： 其中，A是式(a)或(b)的基团： 其中，R代表氢或卤素原子，-S(O)z(C1-C4)烷基，-NHSO2(C1-C4)烷基，-SO2NH(C1-C4)烷基，-NHSO2苯基-(C1-C4)烷基或-NHSO2苯基，所述苯可能被卤素原子，(C1-C4)烷基或(C1-C4)氧代基取代；R1代表氢原子或(C1-C4)烷基，-CO(C1-C4)烷基，苯基-(C1-C4)烷基或-CO-苯基，所述苯也可能被卤素原子或(C1-C4)氧代基取代；R2是氢原子或-SO2(C1-C4)烷基，-SO2苯基-(C1-C4)烷基或-SO2苯基；X完成一个由5到8个原子组成的环，该环饱和或不饱和，可能被一个或两个(C1-C4)烷基取代，并带有一个或两个羰基基团；n，m和z独立地为0，1或2；R3代表氢或卤素原子，(C1-C6)烷基，(C1-C4)氧代基，-COO(C1-C4)烷基，-CO(C1-C4)烷基，-NHSO2(C1-C4)烷基，-NHSO2苯基-(C1-C4)烷基，-NO2，-CN，-CONR4R5，-COOH或4,5-二氢-1,3-噁唑-2-基或4,4-二甲基-4,5-二氢-1,3-噁唑-2-基；R4和R5独立地代表氢原子，苯基，(C1-C4)烷基或苯基-(C1-C4)烷基，或R4和R5与它们所连接的氮原子可以总共形成一个由5到7个原子组成的环；以及它们的盐或溶剂合物，含有它们的制药组合物，制备它们的过程以及在该过程中的中间体。
• N-SULFONYLUREA APOPTOSIS PROMOTERS
  申请人：Elmore Steven W.

  公开号：US20080146572A1

  公开（公告）日：2008-06-19

  Compounds having the formula are apoptosis promoters. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物是凋亡促进剂。还公开了制备这些化合物的方法，含有这些化合物的组合物以及使用这些化合物进行治疗的方法。
• Asymmetric Intramolecular Hydroalkylation of Internal Olefin with Cycloalkanone to Directly Access Polycyclic Systems
  作者：Ai‐Fang Wang、Jin‐Miao Tian、Xiao‐Jing Zhao、Zi‐Hao Li、Ye Zhang、Ka Lu、Hong Wang、Shu‐Yu Zhang、Yong‐Qiang Tu、Tong‐Mei Ding、Yu‐Yang Xie

  DOI：10.1002/anie.202308858

  日期：2023.9.25

  We developed a novel SPD-NH2 organocatalyst that works cooperatively with a PdII complex to catalyze the asymmetric intramolecular hydroalkylation. It demonstrates great reactivity, enantio- and diastereoselectivity (up to 99 % ee and 20 : 1 dr). Moreover, bridged or fused bicyclic systems can be conveniently transformed into diverse di-, tri-, and tetracyclic scaffolds for further conversion into

  我们开发了一种新型SPD-NH 2有机催化剂，它与Pd II配合物协同作用，催化不对称分子内加氢烷基化。它具有出色的反应活性、对映选择性和非对映选择性（高达 99 % ee 和 20 : 1 dr）。此外，桥联或稠合双环系统可以方便地转化为不同的二环、三环和四环支架，以进一步转化为生物学上重要的化合物。